GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • European Respiratory Society (ERS)  (2)
  • O'Donnell, Denis E.  (2)
  • 1
    Online Resource
    Online Resource
    Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement
    European Respiratory Society (ERS) ; 2016
    In:  European Respiratory Journal Vol. 47, No. 2 ( 2016-02), p. 429-460
    Details
    In: European Respiratory Journal, European Respiratory Society (ERS), Vol. 47, No. 2 ( 2016-02), p. 429-460
    Abstract: This document reviews 1) the measurement properties of commonly used exercise tests in patients with chronic respiratory diseases and 2) published studies on their utilty and/or evaluation obtained from MEDLINE and Cochrane Library searches between 1990 and March 2015. Exercise tests are reliable and consistently responsive to rehabilitative and pharmacological interventions. Thresholds for clinically important changes in performance are available for several tests. In pulmonary arterial hypertension, the 6-min walk test (6MWT), peak oxygen uptake and ventilation/carbon dioxide output indices appear to be the variables most responsive to vasodilators. While bronchodilators do not always show clinically relevant effects in chronic obstructive pulmonary disease, high-intensity constant work-rate (endurance) tests (CWRET) are considerably more responsive than incremental exercise tests and 6MWTs. High-intensity CWRETs need to be standardised to reduce interindividual variability. Additional physiological information and responsiveness can be obtained from isotime measurements, particularly of inspiratory capacity and dyspnoea. Less evidence is available for the endurance shuttle walk test. Although the incremental shuttle walk test and 6MWT are reliable and less expensive than cardiopulmonary exercise testing, two repetitions are needed at baseline. All exercise tests are safe when recommended precautions are followed, with evidence suggesting that no test is safer than others.
    Type of Medium: Online Resource
    ISSN: 0903-1936 , 1399-3003
    URL: Article
    DOI: 10.1183/13993003.00745-2015
    Language: English
    Publisher: European Respiratory Society (ERS)
    Publication Date: 2016
    detail.hit.zdb_id: 2834928-3
    detail.hit.zdb_id: 1499101-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD
    European Respiratory Society (ERS) ; 2017
    In:  European Respiratory Journal Vol. 49, No. 4 ( 2017-04), p. 1601348-
    Details
    In: European Respiratory Journal, European Respiratory Society (ERS), Vol. 49, No. 4 ( 2017-04), p. 1601348-
    Abstract: Two replicate, double-blind, 6-week, incomplete-crossover studies (MORACTO 1 and 2) assessed the effects of tiotropium/olodaterol on inspiratory capacity and exercise endurance time in patients with moderate to severe chronic obstructive pulmonary disease. For each patient, four of five treatments were administered once daily for 6 weeks, with a 21-day washout between treatments: tiotropium/olodaterol 2.5/5 µg or 5/5 µg, tiotropium 5 µg, olodaterol 5 µg or placebo, all via the Respimat inhaler. Primary outcomes were inspiratory capacity prior to exercise and exercise endurance time during constant work-rate cycle ergometry to symptom limitation at 75% of peak incremental work rate after 6 weeks (2 h post-dose). 295 and 291 patients were treated in MORACTO 1 and 2, respectively. Tiotropium/olodaterol 2.5/5 and 5/5 µg provided significant improvements in inspiratory capacity versus placebo and monotherapies (p 〈 0.0001), and significant improvements in exercise endurance time versus placebo (p 〈 0.0001). Intensity of breathing discomfort was reduced following both doses of tiotropium/olodaterol versus placebo (p 〈 0.0001). Once-daily tiotropium/olodaterol yielded improvements in lung hyperinflation versus placebo and statistically significant improvements versus monotherapies. Tiotropium/olodaterol also showed improvements in dyspnoea and exercise tolerance versus placebo but not consistently versus monotherapies.
    Type of Medium: Online Resource
    ISSN: 0903-1936 , 1399-3003
    URL: Article
    URL: Article
    URL: Article
    DOI: 10.1183/13993003.01348-2016
    DOI: 10.1183/13993003.01348-2016.Supp1
    DOI: 10.1183/13993003.01348-2016.Supp2
    Language: English
    Publisher: European Respiratory Society (ERS)
    Publication Date: 2017
    detail.hit.zdb_id: 2834928-3
    detail.hit.zdb_id: 1499101-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...